title: Lifitegrast, Bezlotoxumab, and Sugammadex sodium.
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Hussar
authors.forename: Robert Scott
authors.initials: RS
authors.lastname: Cheeseman
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D057134:Antibodies, Neutralizing / Q000627:therapeutic use*; D000080908:Broadly Neutralizing Antibodies; D003015:Clostridium Infections / Q000188:drug therapy; D015352:Dry Eye Syndromes / Q000188:drug therapy; D006801:Humans; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D009883:Ophthalmic Solutions / Q000627:therapeutic use*; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D000077122:Sugammadex / Q000627:therapeutic use*; D013450:Sulfones / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing; D000080908:Broadly Neutralizing Antibodies; D009465:Neuromuscular Agents; D009883:Ophthalmic Solutions; D013450:Sulfones; C575157:lifitegrast; D000077122:Sugammadex; D010649:Phenylalanine; C000613978:bezlotoxumab